Plain-English translation of NCT06780111 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a type of immunotherapy medication that helps your immune system fight cancer, combined with different chemotherapy or targeted treatment approaches. Researchers want to see which combination works best and is safest for people with advanced esophageal squamous cell cancer (a type of cancer in the swallowing tube). You would receive the medication through IV infusions over about 2 years while doctors monitor how well it's working.
People with advanced esophageal squamous cell cancer that cannot be surgically removed have very few good treatment options. This trial exists to see whether adding this immunotherapy medication to existing chemotherapy treatments, or combining it with newer targeted drugs, can help more patients live longer and with fewer side effects.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication every 2 to 3 weeks (depending on which study arm you're assigned to), either alone or combined with chemotherapy, for up to about 2 years. You'll have regular visits to your study center for blood tests, imaging scans to check how your cancer is responding, and to monitor for any side effects. The trial will track your health closely throughout the treatment period to see how well the combination is working for you.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States
Brazil
Chile